Durvalumab (Trademark Imfinzi) Bladder cancer is the 9th most common type of cancer in the world with 430,000 new cases alone diagnosed in 2012 according to World Cancer Research Fund International. Previously patients with bladder cancer, urothelial carcinoma, (UC) had two main options: standard platinum containing chemotherapy, and… Spread the love
Cancer Research UK (CRUK) in conjunction with Astex has begun a Phase I/II Trial to measure the success of a DNA Methyltransferase (DNMT) inhibitor can halt the progress of bladder cancer proving resistant to chemotherapy.
Is it time for urologist to begin to rethink the radical cystectomy, and begin to explore trimodality therapy? Maybe, maybe not, depends on who you ask. Let’s go over a few things first before we jump right in though: